

Genetic Ca Therapies May Hinge on Validated Tests

BY KERRI WACHTER

GAITHERSBURG, MD. — Cancer therapies targeting specific genetic mutations could be required to have corresponding validated diagnostic tests before the therapies can gain approval in the United States, judging by the 7-1 vote of a Food and Drug Administration advisory committee.

The Oncologic Drugs Advisory Committee agreed with the agency that a validated test for the Bcr-Abl T3151 mutation is required before omacetaxine mepesuccinate (Omapro)—a drug targeting that mutation—can be considered for approval.

ChemGenex Pharmaceuticals, a company with offices in Australia and Menlo Park, Calif., is seeking approval of omacetaxine for the treatment of adults with chronic myeloid leukemia (CML) after failure on prior therapy with imatinib (Gleevec) and with the Bcr-Abl T3151 mutation.

ChemGenex announced later that it had received a complete response letter from the FDA, which did not ask for a new trial or data on additional patients. The company said that it hoped to meet with the FDA to address the issues raised by the advisory committee.

The vote is an important one in light of the growing number of therapies targeting specific genetic mutations. ODAC chair Dr. S. Gail Eckhardt noted that the indication for this drug is molecularly defined—failure on imatinib and the T3151 mutation—and that the question of related diagnostic tests will come up more frequently. Dr. Eckhardt is head of medical oncology at the University of Colorado in Denver.

The T3151 mutation is thought to be a marker of tyrosine kinase inhibitor resistance. Patients with the mutation do not respond to any of the three approved therapies for CML and have a poor prognosis. T3151 mutation testing is available at a number of laboratories but is not standardized among facilities.

Omacetaxine, a new molecular entity and first in a class of cephalotaxines, is a synthetic formulation of homoharringtonine, a drug isolated from the evergreen tree *Cephalotaxus* in China.

The application to the FDA was based on the response rates in a single-arm trial in 66 patients deemed to have the T3151 mutation. In the open-label phase II dosing study CML-202, patients were given subcutaneous omacetaxine 1.25 mg/m² for 14 days of a 28-day cycle. If there was a hematologic response, patients received subcutaneous omacetaxine 1.25 mg/m² twice daily for 7 days of a 28-day cycle.

Patients in chronic, accelerated, or myeloid blast phases of CML were included in the study.

Prior imatinib therapy had to have failed, and the T3151 mutation had to be identified and confirmed prior to study enrollment.

Study end points included major cytogenetic response or complete hematologic response for patients with chronic phase CML and overall hematologic response (complete hematologic response, no evidence of leukemia, return to chronic phase) for patients in the accelerated or blast phases.

The study included 40 patients in the chronic phase, 16 in the accelerated phase, and 10 in the blast phase.

All of the patients were determined to have the T3151 mutation, but only 43 had central laboratory confirmation of T3151 status, meaning that roughly a third of the patients failed to meet at least one of the study criteria.

Perhaps more importantly, 10 patients who were initially identified as having the T3151 mutation were later determined by the central laboratories not to have the mutation.

The agency's primary concern was the use of multiple assay methods for the detection of T3151 mutation without any bridging studies between the tests to assess reliability, reproducibility, and concordance of results.

"The lack of having a uniform in vitro diagnostic test creates uncertainty about patient selection both in this trial and, more importantly, in a post-approval setting," the agency wrote in its charge to the committee.

The majority of panel members expressed the same concerns.

The agency also expressed concern that the results of a small, single-arm incomplete efficacy trial were insufficient for approval, given uncertainty in response determination and duration, and uncertainty of the clinical meaningfulness of response rates.

Among patients in the chronic phase, 25% had a major cytogenetic response with 6-month duration, and 85% had a complete hematologic response with 10-month duration.

Among those in the accelerated phase, 37% had an overall hematologic response with a 7-month duration.

Among those in the blast phase, 30% had an overall hematologic response with a 2-month duration.

However, several committee members noted that the numbers of patients, particularly in the accelerated and blast groups, were too small for meaningful analysis.

Disclosures: Members of FDA advisory panels have been cleared of potential conflicts of interest by the FDA prior to the meeting.

The vote is an important one in light of the growing number of therapies targeting specific genetic mutations. The question of related diagnostic tests will come up more frequently.

Internal Medicine News

President, IMNG Alan J. Imhoff

Editor in Chief Mary Jo M. Dales

Executive Editors Denise Fulton, Kathy Scarbeck

Managing Editor Calvin Pierce

Deputy Managing Editor Leanne Sullivan

Senior Editors Christina Chase, Kathryn DeMott, Jeff Evans, Lori Buckner Farmer, Catherine Hackett, Keith Haglund, Gina L. Henderson, Sally Koch Kubetin, Teresa Lassman, Mark S. Lesney, Jane Salodof MacNeil, Renée Matthews, Catherine Cooper Nellist, Amy Pfeiffer, Terry Rudd, Elizabeth Wood

Associate Editors Felicia Rosenblatt Black, Therese Borden, Lorinda Bullock, Jay C. Cherniak, Richard Franki, Virginia Ingram-Wells, Jane Locastro, Carol Nicotera-Ward, Markette Smith

Reporters *Chicago:* Patrice Wendling; *Denver:* Bruce Jancin; *Germany:* Jennie Smith; *Los Angeles:* Betsy Bates; *Miami:* Damian McNamara; *Mid-Atlantic:* Michele G. Sullivan; *New England:* Diana Mahoney; *New York:* Mary Ellen Schneider; *Philadelphia:* Mitchel L. Zoler; *San Diego:* Doug Brunk; *San Francisco:* Sherry Boschert, Robert Finn; *Washington:* Alicia Ault, Elizabeth Mechcatie, Heidi Splete, Miriam E. Tucker, Kerri Wachter

Contributing Writers Christine Kilgore, Mary Ann Moon

Project Manager Susan D. Hite

Assignments Manager Megan Evans

Address Changes Fax change of address (with old mailing label) to 973-290-8245 or e-mail change to subs@elsevier.com

Reprints Call 240-221-2419

Editorial Offices 5635 Fishers Lane, Suite 6000, Rockville, MD 20852, 877-524-9336, imnews@elsevier.com

Director of Information Technology Doug Sullivan

Senior Systems Administrators Lee J. Unger, Kreg M. Williams

Systems Administrator/Application Support Peter Ayinde

Accounts Payable Coordinator Daniela Silva

Executive Director, Operations Jim Chicca

Director, Production/Manufacturing Yvonne Evans

Production Manager Judi Sheffer

Production Specialists Maria Aquino, Anthony Draper, Rebecca Slebodnik

Creative Director Louise A. Koenig

Design Supervisor Elizabeth Byrne Lobdell

Senior Designers Sarah L.G. Breenen, Yenling Liu

Designer Lisa M. Marfori

Photo Editor Catherine Harrell

Senior Electronic Production Engineer Jon Li

Sales Director, IMNG

Mark E. Altier, 973-290-8220, m.altier@elsevier.com

Sales Manager, Internal Medicine News

Phil Soufleris, 973-290-8224, p.soufleris@elsevier.com

National Account Managers

Kathleen Hiltz, 973-290-8219, k.hiltz@elsevier.com

Cathy McGill, 973-290-8221, c.mcgill@elsevier.com

Classified Sales Manager, IMNG

Robert Zwicker 973-290-8226,

fax 973-290-8250,

r.zwicker@elsevier.com

Advertising Offices

60 Columbia Rd., Bldg. B, 2nd flr.,

Morristown, NJ 07960,

973-290-8200, fax 973-290-8250

Sr. Program Manager, Customized Programs
Mailika Wicks

Circulation Analyst Barbara Cavallaro,
973-290-8253, b.cavallaro@elsevier.com

Program/Marketing Manager Jennifer Eckert

Business Controller Dennis Quirk

Adv. Services Manager Joan Friedman

Manager, Administration/Conventions

Lynne Kalish

Receptionist Linda Wilson

INTERNAL MEDICINE NEWS is an independent newspaper that provides the practicing internist with timely and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and the physician's practice.

The ideas and opinions expressed in INTERNAL MEDICINE NEWS do not necessarily reflect those of the Publisher. Elsevier Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

POSTMASTER Send changes of address (with old mailing label) to INTERNAL MEDICINE NEWS Circulation, 60 Columbia Rd., Bldg. B, 2nd flr., Morristown, NJ 07960.

INTERNAL MEDICINE NEWS (ISSN 1097-8690) is published semimonthly by Elsevier Inc., 60 Columbia Rd., Bldg. B, 2nd flr., Morristown, NJ 07960, 973-290-8200, fax 973-290-8250. Subscription price is \$139.00 per year. Periodicals postage paid at Morristown, NJ, and additional offices.

Founding Publisher: Jack O. Scher
Founding Editor: William Rubin

©Copyright 2010, by Elsevier Inc.



INTERNATIONAL
MEDICAL NEWS
GROUP



VITAL SIGNS

Concerns Remain After Health Care Reform Passage

Will each of the following get better, not change, or get worse than if no health care bill passed?

	Get better	Not change	Get worse
Health care coverage	44%	13%	40%
Overall health of Americans	40%	24%	35%
Overall quality of health care	34%	20%	44%
Overall costs of health care	29%	14%	55%
Federal budget deficit	23%	14%	61%

Notes: Based on a USA Today/Gallup poll of 1,033 adults conducted March 26-28. Don't know/refused responses not shown.

Source: Gallup Inc.